| Symbol | BIVI |
|---|---|
| Name | BIOVIE INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 680 W NYE LANE,SUITE 204, CARSON CITY, Nevada, 89703, United States |
| Telephone | +1 775 - 888-3162 |
| Fax | — |
| — | |
| Website | https://www.bioviepharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | BioVie Inc is a company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is currently focused on developing and commercializing BIV201, a novel investigational approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism. Additional info from NASDAQ: |
BioVie Inc. - BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinsons Disease ahead of Topline Data in 2Q26, on May 7, 2026
Read moreBioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinsons Disease ahead of Topline Data in 2Q26, on May 7, 2026
Read moreBioVie Inc. - BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting
Read moreBioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting
Read moreNew Form SCHEDULE 13D - BIOVIE INC. <b>Filed:</b> 2026-03-25 <b>AccNo:</b> 0001520138-26-000086 <b>Size:</b> 127 KB
Read moreBioVie Inc. - BioVie Announces Abstract Accepted for Presentation at AD/PD 2026
Read moreBioVie Inc. - Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on March 4
Read moreBioVie Inc. - BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting
Read morePalumbo Joseph M 🟢 acquired 132.0K shares (1 derivative) of BIOVIE INC. (BIVI) at $1.31 Transaction Date: Jan 05, 2026 | Filing ID: 000024
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06847191 | NE3107 in Adults With Neurological Symptoms of Long COVID | Phase2 | Long COVID | Recruiting | 2025-04-29 | 2026-08-01 | ClinicalTrials.gov |
| NCT06757010 | A Study of NE3107 in Early Parkinson's | Phase2 | Parkinsons Disease (PD) | Active_Not_Recruiting | 2025-03-26 | 2026-05-31 | ClinicalTrials.gov |
| NCT05970575 | Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Trau… | Phase2 | Traumatic Brain Injury | Terminated | 2023-12-21 | 2025-07-21 | ClinicalTrials.gov |
| NCT05227820 | Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatmen… | Phase2 | Alzheimer Disease | Completed | 2022-01-19 | 2022-08-20 | ClinicalTrials.gov |
| NCT05083260 | NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa | Phase1 | Parkinson Disease | Completed | 2022-01-04 | 2023-01-04 | ClinicalTrials.gov |
| NCT04669028 | A Phase 3 Study of NE3107 in Probable Alzheimer's Disease | Phase3 | Alzheimer Disease | Completed | 2021-08-05 | 2023-10-25 | ClinicalTrials.gov |
| NCT04112199 | A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patient… | Phase2 | Ascites | Terminated | 2021-06-17 | 2023-05-08 | ClinicalTrials.gov |
| NCT03107091 | Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Asc… | Phase2 | Cirrhosis | Completed | 2017-07-15 | 2019-04-25 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| NE3107 | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| Placebo | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| NE3107 | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| Placebo | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| NE3107 | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| Placebo | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| NE3107 | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| Placebo | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| NE3107 | Other | Phase PHASE2 | Parkinsons Disease (PD) | ACTIVE_NOT_RECRUITING | NCT06757010 |
| placebo | DRUG | Phase PHASE1 | Parkinson Disease | COMPLETED | NCT05083260 |
| Placebo | DRUG | Phase PHASE2 | Long COVID | RECRUITING | NCT06847191 |
| NE3107 | DRUG | Phase PHASE2 | Long COVID | RECRUITING | NCT06847191 |
| BIV201 continuous infusion | DRUG | Phase PHASE2 | Ascites | TERMINATED | NCT04112199 |
| Terlipressin acetate continuous infusion | DRUG | Phase PHASE2 | Cirrhosis | COMPLETED | NCT03107091 |